This Article Full Text (PDF) All Versions of this Article: 1352458509102771v1 15/6/741    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kobelt, G Articles by Lindgren, P Search for Related Content PubMed PubMed Citation Articles by Kobelt, G Articles by Lindgren, P Social Bookmarking                         What's this?

The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions

Department of Orthopedics, Lund University, Lund, Sweden; European Health Economics, Mulhouse, Francegisela.kobelt{at}he-europe.com

B Texier-Richard

European Health Economics, Mulhouse, France

P Lindgren

I3/Innovus, Stockholm, Sweden; Karolinska Institute, Stockholm, Sweden

Objective

To evaluate the long-term costs and quality of life (QoL) with and without disease-modifying treatments (DMTs) of patients with multiple sclerosis (MS).

Methods

Data on resource consumption, productivity losses, QoL (utility), and fatigue were collected from 1355 patients registered with a patient association and descriptive analyses was performed.

A Markov model was developed to estimate costs and utility over 20 years using the survey data. Disease progression without DMTs was taken from an epidemiological cohort in France (EDMUS cohort, LYON). Progression under DMTs was estimated from the Stockholm MS registry. Results are presented as cost per quality-adjusted life-years (QALYs), from the societal perspective, in EUR2007, discounted at 3%.

Results

Mean Expanded Disability Status Scale (EDSS) was 4.4 and mean total annual costs per patient were EUR44,400, of which 47% were productivity losses and 11% informal care. Public payers cover an estimated 48% of costs. Mean utility was 0.52, and the loss compared with the normal population was estimated at 0.28. Costs and utility ranged from EUR16,000 and 0.79 at EDSS 1 to EUR76,000 and 0.11 at EDSS 8–9.

Over 20 years, costs were estimated at EUR429,000 and QALYs at 8.96 for patients without DMTs and at EUR433,207 and 9.24 QALYs if all patients were starting treated with DMTs at EDSS 1–3.

Conclusion

Although the data for this analysis come from different sources, the results indicate that the cost increase with DMTs is moderate.

Key Words: cost • France • multiple sclerosis • registries • utility

This version was published on June 1, 2009

Multiple Sclerosis, Vol. 15, No. 6, 741-751 (2009)
DOI: 10.1177/1352458509102771


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?